Interim CFO of Conduit Pharmaceuticals, Bligh James, has engaged in a transaction involving the company's stock on November 18, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Bligh James, but without further information, the impact on his total number of shares held after the action cannot be determined.

Interim CFO of Conduit Pharmaceuticals, Bligh James, has engaged in a transaction involving the company's stock on November 18, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Bligh James, but without further information, the impact on his total number of shares held after the action cannot be determined.